Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for Its Single-Shot Chikungunya Vaccine
Declaration of Shares and Voting Rights April 30, 2024 - VALNEVA SE
Declaration of Voting Rights - Valneva SE, March 2024
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
Valneva GAAP EPS of -€0.73, Revenue of €153.71M; Updates FY24 Guidance
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility With Deerfield and OrbiMed
VALNEVA Declaration of Shares and Voting Rights - February 29, 2024
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
Valneva's net loss of 18.1 million euros in the first quarter increased 54% year-on-year
Glonghui, May 4 丨 Valneva (VALN.US) had a net loss of 18.1 million euros in the first quarter, with revenue of 33.5 million euros, up 53.7% year on year; product sales were 32.1 million euros, up 98.6% year on year; driven by IXIARO and DUKORAL sales, sales of these two products increased more than four times year on year. The company reiterated the 2023 financial guidelines, which expected total revenue and other revenue to be between 220 million euros and 260 million euros, including product sales of 130 million to 150 million euros, including product sales of 130 million to 150 million euros and Of 90 million to 110 million euros
Valneva, Pfizer Delay End Date of Lyme Disease Vaccine Phase 3 Trial to 2025
Valneva's revenue reached 361 million euros in 2022, and product sales increased 82.3% year-on-year
Gronghui, March 23, 丨 Valneva announced 2022 results. As of December 31, 2022, the total revenue was 361 million euros, compared to 348 million euros in 2021, an increase of 3.79% over the previous year. Among them, product sales reached 115 million euros, an increase of 82.3% over the previous year, including travel vaccine sales of 85.2 million euros and COVID-19 vaccine sales of 29.6 million euros; other revenue of 247 million euros mainly came from confirmed revenue related to previous COVID-19 vaccine supply agreements. The company's adjusted EBITDA loss was 6,920 euros.
Pfizer, Valneva Removes ~50% Participants in Lyme Disease Vaccine Trial on Violation Woes
Valneva Stock Rises as It Seeks FDA Approval of Single-shot Chikungunya Vaccine
Valneva Reports Q3 Results; Reaffirms FY22 Guidance
Valneva Upsizes Stock Offering to Raise ~€102.9M to Fund Lyme/chikungunya Vaccines
Valneva (NASDAQ:VALN) (OTCPK:INRLF) upsized an offering to raise ~€102.9M (~$99.9M) from the previously expected $40M due to excess demand. The French vaccine maker is pricing of 21M ordinary shares i
Valneva Stock Dips as US DoD Ends Japanese Encephalitis Vaccine Ixiaro Supply Deal
Valneva (NASDAQ:VALN) (OTCPK:INRLF) (OTC:VNVLF) said the U.S. Department of Defense (DoD) decided not to exercise the second option year of the contract to get the company's Japanese encephalitis (JE)
Valneva launches up to $75M at-the-market ADS offering program
Valneva (NASDAQ:VALN) entered in a new financing program to offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $75.0M of American Deposi
No Data